Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

717 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O'Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P. Moser T, et al. Front Immunol. 2021 Aug 26;12:718895. doi: 10.3389/fimmu.2021.718895. eCollection 2021. Front Immunol. 2021. PMID: 34512642 Free PMC article. Clinical Trial.
The emerging role of CDK4/6i in HER2-positive breast cancer.
O'Sullivan CC, Suman VJ, Goetz MP. O'Sullivan CC, et al. Ther Adv Med Oncol. 2019 Nov 27;11:1758835919887665. doi: 10.1177/1758835919887665. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31832106 Free PMC article. Review.
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. O'Sullivan CC, et al. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. Future Oncol. 2021. PMID: 34636255 Free PMC article.
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Haddad TC, He J, O'Sullivan CC, Chen B, Northfelt D, Dueck AC, Ballman KV, Tenner KS, Linden H, Sparano JA, Hopkins JO, De Silva C, Perez EA, Haluska P, Goetz MP. Haddad TC, et al. Breast Cancer Res Treat. 2021 Jul;188(2):477-487. doi: 10.1007/s10549-021-06221-8. Epub 2021 Apr 14. Breast Cancer Res Treat. 2021. PMID: 33852121 Free PMC article. Clinical Trial.
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM, Liddell S, Ferre RAL, O'Sullivan CC, Ruddy KJ, Haddad TC, Hobday TJ, Peethambaram PP, Liu MC, Goetz MP, Giridhar KV. Choong GM, et al. Breast Cancer Res Treat. 2022 Nov;196(1):229-237. doi: 10.1007/s10549-022-06713-1. Epub 2022 Aug 31. Breast Cancer Res Treat. 2022. PMID: 36045271 Free PMC article.
717 results